Invivyd (NASDAQ:IVVD – Get Free Report)‘s stock had its “buy” rating restated by analysts at D. Boral Capital in a report issued on Thursday,Benzinga reports. They presently have a $9.00 price target ...
NASDAQ:IVVD opened at $0.72 on Thursday. Invivyd has a 52 week low of $0.35 and a 52 week high of $4.74. The firm has a market cap of $86.12 million, a price-to-earnings ratio of -0.37 and a beta ...
Reports FY24 revenue $25.3M, consensus $25.15M. “We are pleased with the significant PEMGARDA revenue growth of 48% in the fourth quarter, ...
PEMGARDA™ (pemivibart) net product revenue of $13.8 million, representing 48% growth over Q3 2024 net product revenue of $9.3 million; full-year 2024 net product revenue totaled $25.4 million2024 year ...
Zacks Investment Research on MSN2d
Invivyd, Inc. (IVVD) Reports Q4 Loss, Tops Revenue EstimatesInvivyd, Inc. (IVVD) came out with a quarterly loss of $0.15 per share versus the Zacks Consensus Estimate of a loss of $0.25. This compares to loss of $0.67 per share a year ago. These figures are ...
March 20, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, today announced financial ...
After hours: March 21 at 7:55:35 PM EDT Loading Chart for IVVD ...
After hours: March 17 at 7:20:49 p.m. EDT ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback